↓ Skip to main content

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

Overview of attention for article published in BMC Cancer, January 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
2 X users

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
Published in
BMC Cancer, January 2022
DOI 10.1186/s12885-021-09028-4
Pubmed ID
Authors

Xi Chen, Haiying Kong, Linxiang Luo, Shuiyun Han, Tao Lei, Haifeng Yu, Na Guo, Cong Li, Shuailing Peng, Xiaowu Dong, Haiyan Yang, Meijuan Wu

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 13%
Researcher 2 13%
Student > Bachelor 1 7%
Student > Master 1 7%
Student > Doctoral Student 1 7%
Other 0 0%
Unknown 8 53%
Readers by discipline Count As %
Medicine and Dentistry 3 20%
Biochemistry, Genetics and Molecular Biology 1 7%
Environmental Science 1 7%
Agricultural and Biological Sciences 1 7%
Engineering 1 7%
Other 0 0%
Unknown 8 53%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2022.
All research outputs
#16,734,944
of 25,392,582 outputs
Outputs from BMC Cancer
#4,116
of 8,973 outputs
Outputs of similar age
#287,044
of 515,556 outputs
Outputs of similar age from BMC Cancer
#76
of 214 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,973 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 515,556 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 214 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.